Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Kimura

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Drug Design, Development and Therapy|September 2, 2017
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the futureDavid Ah Whiteman, Alan Kimura
Clinical and Vaccine Immunology : CVI|December 24, 2010
Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolatesAlan Kimura, Daniela Toneatto, Annett Kleinschmidt, et al.
Experimental Eye Research|April 27, 2004
Central retinal artery occlusion. Retinal survival timeSohan Singh Hayreh, M Bridget Zimmerman, Alan Kimura, et al.
BMC Health Services Research|May 24, 2017
Development and validation of the angiotensin-converting enzyme inhibitor (ACEI) induced angioedema investigator rating scale and proposed discharge criteriaNicola Bonner, Charlotte Panter, Alan Kimura, et al.
Molecular Genetics and Metabolism|December 23, 2006
A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)Joseph Muenzer, Muge Gucsavas-Calikoglu, Shawn E McCandless, et al.
BMC Ophthalmology|September 18, 2023
Real-world treatment patterns and economic burden of post-cataract macular edemaGina Ahmadyar, Josh J Carlson, Alan Kimura, et al.
Lancet (London, England)|January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsTimo Vesikari, Susanna Esposito, Roman Prymula, et al.
Vaccine|October 21, 2006
Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adultsScott A Halperin, Joanne M Langley, Bruce Smith, et al.
Annals of Tropical Paediatrics|March 22, 2003
High burden of invasive Streptococcus agalactiae disease in South African infantsShabir A Madhi, Kholeka Radebe, Heather Crewe-Brown, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 30, 2017
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway AngioedemaRichard Sinert, Phillip Levy, Jonathan A Bernstein, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Drug Design, Development and Therapy|September 2, 2017
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the futureDavid Ah Whiteman, Alan Kimura
Clinical and Vaccine Immunology : CVI|December 24, 2010
Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolatesAlan Kimura, Daniela Toneatto, Annett Kleinschmidt, et al.
Experimental Eye Research|April 27, 2004
Central retinal artery occlusion. Retinal survival timeSohan Singh Hayreh, M Bridget Zimmerman, Alan Kimura, et al.
BMC Health Services Research|May 24, 2017
Development and validation of the angiotensin-converting enzyme inhibitor (ACEI) induced angioedema investigator rating scale and proposed discharge criteriaNicola Bonner, Charlotte Panter, Alan Kimura, et al.
Molecular Genetics and Metabolism|December 23, 2006
A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)Joseph Muenzer, Muge Gucsavas-Calikoglu, Shawn E McCandless, et al.
BMC Ophthalmology|September 18, 2023
Real-world treatment patterns and economic burden of post-cataract macular edemaGina Ahmadyar, Josh J Carlson, Alan Kimura, et al.
Lancet (London, England)|January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsTimo Vesikari, Susanna Esposito, Roman Prymula, et al.
Vaccine|October 21, 2006
Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adultsScott A Halperin, Joanne M Langley, Bruce Smith, et al.
Annals of Tropical Paediatrics|March 22, 2003
High burden of invasive Streptococcus agalactiae disease in South African infantsShabir A Madhi, Kholeka Radebe, Heather Crewe-Brown, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 30, 2017
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway AngioedemaRichard Sinert, Phillip Levy, Jonathan A Bernstein, et al.
Pageof 2